Is terlipressin (Glypressin) indicated for a patient with portal‑hepatic disease who has a common bile duct (CBD) stent?

Use of Terlipressin (Glypressin) in Portal Hypertension with CBD Stent

Terlipressin is NOT the first-line vasoactive drug for portal hypertension complications; octreotide should be used instead due to its superior safety profile, and the presence of a CBD stent does not change this recommendation. 1

Primary Recommendation

According to the 2024 AGA Clinical Practice Update, octreotide is the vasoactive drug of choice in managing variceal hemorrhage based on its safety profile 1. This guideline explicitly states that terlipressin carries a 2.39-fold increase in adverse events compared to octreotide or somatostatin, including:

• Abdominal pain
• Chest pain
• Diarrhea
• Hyponatremia
• Respiratory failure
• Myocardial ischemia
• Intestinal ischemia 1

Critical Safety Considerations

Terlipressin is contraindicated in patients with:

• Hypoxia or worsening respiratory symptoms
• Ongoing coronary, peripheral, or mesenteric ischemia 1

The presence of a CBD stent does not create a specific indication for terlipressin over octreotide. While one small case series from 2009 reported successful use of terlipressin for hemobilia during ERCP in portal biliopathy patients 2, this represents anecdotal evidence from 4 cases and does not override current guideline recommendations prioritizing octreotide.

When Terlipressin Might Be Considered

If octreotide fails to control bleeding or if there is a suboptimal hemodynamic response, terlipressin may be considered as a second-line agent. The 2024 guidelines note that terlipressin can reduce hepatic venous pressure gradient more effectively than increasing somatostatin doses in refractory cases 1.

If terlipressin must be used, continuous infusion (4 mg/24h) is preferred over bolus dosing (2 mg every 4h) as it:

• Allows lower total doses
• Results in fewer adverse events
• Provides more sustained hemodynamic effects 1

However, recent 2025 data suggests that continuous infusion alone may not provide adequate rapid portal pressure reduction needed for acute variceal bleeding 3, and the optimal dosing strategy remains under investigation.

Clinical Algorithm

1. First-line: Use octreotide for any portal hypertension-related bleeding
2. Monitor closely: Assess bleeding control within 24 hours
3. If refractory: Consider terlipressin as continuous infusion only after excluding contraindications
4. Screen for: Cardiac ischemia, respiratory compromise, mesenteric ischemia before initiating terlipressin
5. Enhanced monitoring needed if: Child-Pugh class C or baseline hyponatremia (recent 2026 data shows 68.9% incidence of hyponatremia in elderly patients) 4

Important Caveat

The FDA drug label information provided 5 refers to glycopyrrolate (GLYRX-PF), which is an anticholinergic agent—NOT terlipressin. This is a completely different medication and should not be confused with Glypressin (terlipressin). Glycopyrrolate has no role in managing portal hypertension or variceal bleeding.

The CBD stent itself does not alter vasoactive drug selection—octreotide remains the preferred agent regardless of biliary instrumentation.